drugset / Trial / NCT03099122
A Study of Thymoglobuline® Induction Therapy in Adult Recipients of Donated After Cardiac Death Kidney Transplant
NaSingle-groupOpen-labelPrevention
Summary
Primary Objective: To investigate the efficacy of the standard dose of Thymoglobuline® induction therapy for preventing acute rejection (AR) after transplantation among recipients of Donated after Cardiac Death (DCD) kidney transplant. Secondary Objectives: * To evaluate delayed graft function (DGF), graft and patient survival after kidney transplant. * To evaluate adverse events of Thymoglobuline® throughout the study. * To explore possible risk factors of AR and DGF in patients with DCD kidney transplant. * To evaluate AR and DGF under different risk stratifications and explore an description optimal induction therapy regimen for recipients of DCD kidney transplant.
Timeline
- Start
- 2017-08-16
- Primary completion
- 2019-11-12
- Completion
- 2019-11-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Thymoglobulin | Protein / enzyme biologic | — | Intravenous |
| Background | Methylprednisolone | Other / unclassified | — | Intravenous |
| Background | Mycophenolate Mofetil | Small molecule | — | Oral |
| Background | Mycophenolate Na | Unknown | — | Oral |
| Background | Prednisone | Other / unclassified | — | Oral |
| Background | Tacrolimus | Small molecule | — | Oral |